RAD001: Clinical Trials

5 completed, 1 terminated. 6 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	6	Completed 5, Terminated 1

Follow RAD001: new trials by email Literature Review of RAD001 trials Research Report on RAD001

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) Everolimus - Renal Angiomyolipoma	Phase 4	Completed	Novartis Pharmaceuticals	4	2023-05-01	2026-10-29
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis RAD001, Exemestane - Oestrogen Receptor Positive Advanced Breast Cancer	Phase 4	Completed	Novartis Pharmaceuticals	52	2013-01-31	2019-07-18
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Everolimus (RAD001) - Metastatic Renal Cell Carcinoma (mRCC)	Phase 4	Completed	Novartis Pharmaceuticals	29	2012-05-21	2017-07-19
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation RAD001, Paclitaxel, Carboplatin - Carcinoma, Large Cell, Neuroendocrine Tumors	Phase 4	Completed	Novartis Pharmaceuticals	49	2011-04-01	2016-03-30
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. RAD001 - Renal Cell Carcinoma	Phase 4	Completed	Novartis Pharmaceuticals	143	2009-11-11	2019-06-24
Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program Basiliximab, Enteric Coated Mycophenolic Acid (MPA), RAD001 - Renal Transplantation	Phase 4	Terminated	Novartis Pharmaceuticals	207	2009-07-01	2014-06-06

Conditions studied

Carcinoma, Renal Cell (2)  ·  Angiomyolipoma (1)  ·  Breast Diseases (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Large Cell (1)  ·  Kidney Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Skin Diseases (1)  ·  Tuberous Sclerosis (1)

Sponsors

Novartis Pharmaceuticals (6)

Countries

Germany (3)  ·  Algeria (1)  ·  Egypt (1)  ·  India (1)  ·  Jordan (1)  ·  Lebanon (1)  ·  Russia (1)  ·  Saudi Arabia (1)  ·  South Africa (1)  ·  Taiwan (1)  ·  Thailand (1)  ·  Tunisia (1)  ·  United Kingdom (1)

Results publications

PMID 28535181, PMID 31536556

NIH funding

2008 (1)